Search Results
, E. , & Marcela Ot’alora , G. ( 2013 ). A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder . Priest , G. , Tanaka , K. , & Weber , Z. ( 1996 ). Paraconsistent logic . Roseman , L. , Nutt , D. J
-drug interactions between psychiatric medications and MDMA or psilocybin: A systematic review . Psychopharmacology , 239 , 1945 – 1976 . https://doi.org/10.1007/s00213-022-06083-y . 10.1007/s00213-022-06083-y
. S. , & Brewerton , T. D. ( 2016 ). Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA . The Lancet Psychiatry, 3 ( 5 ), 481 – 488 . doi: 10.1016/S2215-0366(15)00576-3 10.1016/S2215
-site crossover study to assess psychological effects of MDMA when administered to healthy volunteers . Retrieved 28 June 2020 from https://mapscontent.s3-us-west-1.amazonaws.com/pdfs/MT1+Santized+for+Website+Protocol+A5V2+Clean+08APR2020.pdf . Muthukumaraswamy
Introduction: pharmacovigilance beyond the individual level? In December 2023 the Multidisciplinary Association for Psychedelic Studies submitted a new drug application to the Food & Drug Administration for the use of MDMA in the treatment of post
-B [2,5-dimethoxy-4-bromophenethylamine] etc.), 5-MeO-DMT (5-methoxy- N,N -dimethyltryptamine), Ayahuasca (or analogues), smoked DMT ( N,N -Dimethyltryptamine), LSD (Lysergic acid diethylamide), MDMA (3,4-Methylenedioxy-methamphetamine), Mescaline
among MDMA and other drug users . Drug and Alcohol Dependence , 96 ( 1–2 ), 99 – 110 . 10.1016/j.drugalcdep.2008.02.003 Han , X. , Wu , X. , Wang , Y. , Sun , Y. , Ding , W. , Cao , M. , ( 2018 ). Alterations of resting-state static and
. ( 2005 ). Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: A multiple regression analysis . Addictive Behaviors , 30 ( 1
, psilocybin, MDMA, and ketamine . The Journal of Neuroscience , 41 ( 5 ), 891 – 900 . https://doi.org/10.1523/jneurosci.1659-20.2020 . 10.1523/JNEUROSCI.1659
for one patient each. Other substances mentioned by some patients included “acid” [lysergic acid diethylamide (LSD)], “ecstasy” [3,4-methylenedioxymethamphetamine (MDMA)], mushrooms, solvents/inhalants, and amphetamines. Only one patient had previous
